-+ 0.00%
-+ 0.00%
-+ 0.00%

REPLIMUNE SHARES MORE THAN DOUBLE TO $11.75 PREMARKET AFTER US FDA ADVISERS BACK CO'S SKIN CANCER DRUG

Reuters·07/31/2026 09:45:12

Please log in to view news